Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis. by Tlsty, T. D. et al.
Proc. Natl. Acad. Sci. USA
Vol. 86, pp. 9441-9445, December 1989
Genetics
Differences in the rates of gene amplification in nontumorigenic
and tumorigenic cell lines as measured by Luria-Delbruck
fluctuation analysis
(genetic fluidity/mutagenesis/mutation rate/rat liver epithelial cells)
THEA D. TLSTY*tt, BARRY H. MARGOLIN*§, AND KAREN LUM*t
*Lineberger Cancer Research Center and Departments of tPathology and §Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill,
NC 27599-7295
Communicated by Allan M. Campbell, September 5, 1989 (receivedfor review June 27, 1989)
ABSTRACT It has been hypothesized that genomic fluidity
is an important component of tumorigenesis. Previous studies
described the relationship between tumorigenicity and one
marker for genomic fluidity, gene amplification. In this report,
these studies are extended with the rat liver epithelial cell lines
to show that: (i) the amplification in these cells arises in a
spontaneous fashion in the population (i.e., the variants de-
tected are not preexisting in the population), and (i) the rate
of spontaneous amplification (mutation), as measured by Lu-
ria-Delbruck fluctuation analysis, is significantly lower in the
nontumorigenic cells than in the tumorigenic cells. The rate was
estimated by using the PO method and the method ofmeans. The
rate of spontaneous amplification of the gene encoding the
multifunctional protein CAD (containing the enzymatic activ-
ities carbamoyl-phosphate synthase, aspartate transcarbam-
ylase, and dihydroorotase) in the highly tumorigenic cells was
significantly greater than that for the nontumorigenic cells,
reaching almost 1 x 10-4 events per cell per generation. The
rate of this mutagenic event is high compared to the rate of
point mutations usually reported in mammalian cells, and its
potential contribution to the tumorigenic process will be dis-
cussed.
Nowell (1) has hypothesized that the acquisition of genetic
instability or lability may be an initiating step in the process
ofproducing malignant cells. The acquired genetic variability
allows for the production of a heterogeneous population and
the subsequent selection of cells with increased malignant
potential. Key to this hypothesis is the proposition that tumor
cells are more genetically unstable than nontumorigenic cells.
To address this point, several previous studies have exam-
ined the rate of point mutations as an indicator of genetic
fluidity and found them to be elevated in tumorigenic cells
(2-4). In contrast, three studies have found that the rate of
point mutation was equivalent in nontransformed and trans-
formed lines as well as between metastatic and nonmetastatic
murine tumor cells (5-7). Taken together, these reports do
not establish a relationship between "genomic fluidity,"
mutability, and tumorigenicity. Because the establishment of
such a relationship between genomic fluidity and tumorige-
nicity could provide a basis for elucidating the cause(s) of
tumor cell heterogeneity, it remains an important question.
To understand the process better, we have used the
detection of amplification of the gene encoding the multi-
functional protein CAD containing the enzymatic activities
carbamoyl-phosphate synthase, aspartate transcarbamylase,
and dihydroorotase as a molecular tool for studying genetic
fluidity of neoplastic cells. Amplification of the CAD gene
occurs when cells are exposed to the cytotoxic drug, N-
(phosphonoacetyl)-L-aspartate (PALA), which inhibits as-
partate transcarbamylase activity (8). Unlike resistance to
methotrexate, which may occur through multiple mecha-
nisms (9), resistance to PALA has only been reported to
occur through amplification of the CAD gene (10). Correla-
tions between amplification and tumorigenicity also have
been investigated at the dihydrofolate reductase locus. An
earlier report by Sager et al. (11) observed that methotrexate-
resistant cells emerged more rapidly from a tumorigenic
population than from a nontumorigenic cell population.
While both Otto et al. (12) and Sager et al. (11) have shown
an increased emergence of drug-resistant colonies in tumor-
igenic cells, to date it has not been shown that the rate of
amplification is different between tumorigenic and nontu-
morigenic cells.
In the present study we utilized the Luria-Delbruck fluc-
tuation analysis (13) for two purposes: to investigate the
nature of the amplification events and, subsequently, to
determine the rate of spontaneous gene amplification in each
of the cell lines. The Luria-Delbruck fluctuation analysis is
a combined experimental and statistical method that allows
one to distinguish between variant cells arising by rare
spontaneous mutations and variant cells arising through
adaptation to an environmental selection (13). The analysis is
based on the variation that is seen in the emergence of
colonies from parallel cultures (14).
Fig. 1 shows a schematic diagram of a fluctuation exper-
iment and the hypothetical results one could obtain when
analyzing a spontaneous mutation. The first set (indicated by
the downward arrow) contains replicate samples in which
aliquots of cells from the parent population are plated directly
into selection medium and analyzed for the number of
resistant colonies that emerge. The colonies on these plates
will represent rare, resistant, preexisting variants. The num-
ber of colonies on each plate should exhibit a Poisson
distribution, and the mean number of colonies per plate will
reflect the prevalence of resistant variants in the parental
population. Replicate platings from the same parent popula-
tion should show variation due only to random sampling; the
variance from these replicate samples should equal the mean.
For the second set, a small number of cells (small enough
to assure no preexisting variants are present) is plated and
allowed to propagate under nonselective conditions for a
given amount of time. When the individual populations have
reached the same cell density plated in set 1, they are
transferred to fresh plates for an even distribution of cells and
placed under selection (in this case PALA). If the drug-
resistant cells are the result of exposure to PALA (i.e.,
Abbreviations: PALA, N-(phosphonoacetyl)-L-aspartate; CAD, the
multifunctional protein containing the enzymatic activities carbam-
oyl-phosphate synthase, aspartate transcarbamylase, and dihydro-
orotase.
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FIG. 1. Schematic diagram of a Luria-Delbruck fluctuation anal-
ysis of a spontaneous mutation event. Set 1 samples the variance of
the parent population; the distribution should be Poisson, and the
variance should equal the mean. Set 2 measures the variance of small
aliquots that have been propagated under nonselective conditions. In
this example a spontaneous mutation event has given rise to the
colonies depicted in each plate. The horizontal arrows in samples 2
and 3 of set 2 indicate mutational events occurring early and late
during the propagation of these cultures, respectively. For further
explanation, see the Introduction.
adaptive), each cell should have a similar probability for
survival in selective media, and the appearance of resistant
variants should be similar in all plates. The variation from
plate to plate would be consistent with the Poisson model. If
the events that lead to resistance are spontaneous, as each
parallel culture expands it will have a given probability for
generating resistant variants with each cell division. In some
cultures the event (amplification) will occur early and many
of the progeny of the resistant cell will be present to form
drug-resistant colonies. In others, the event will occur during
one of the last cell divisions, and few drug-resistant progeny
will result. The appearance of variants will be random, and
the contribution to the surviving colonies when the cells are
placed in selection will vary greatly depending on when in the
propagation of the population the mutation occurred. Statis-
tical analysis of this variation allows one to calculate the rate
of appearance of spontaneous variants.
MATERIALS AND METHODS
Cells and Culture Conditions. Rat liver epithelial cell lines
were derived and grown as described (12, 15, 16). The
aliquots of frozen cells used in these experiments were the
same as those used for previous and ongoing tumorigenicity
studies (16). WB20, GN5, and GP9 cells exhibited 0%, 11-
50%, and 100% tumorigenicity upon injection into isogenic
newborn rats (16) and plating efficiencies of 0.78, 0.84, and
0.55, respectively. At the conclusion of these experiments,
several ofthese cell lines were reconfirmed in their respective
tumorigenicities.
Drug Selections. Selection experiments were as described
(12). The incidence of PALA resistance is the proportion of
attached cells that gave rise to resistant colonies and, thus, is
relative to the plating efficiencies of the cells in medium
without drug (100% survival). LD50 values represent the
concentration of PALA that allows 50% survival. LD50
values for the WB20, GN5, and GP9 cells are 12.5, 8, and 9 ,4M
PALA, respectively.
Subcloning PALA-Resistant Lines. Cells from individual
PALA-resistant colonies were expanded in 9x LD50 PALA-
containing medium. Genomic DNA was isolated from a
portion of these cells and analyzed for the gene copy number
(12, 17).
Determination of Experimental Parameters. In this paper
we have used both the P0 method and the method of means
for measuring the mutation rate in mammalian cells. The PO
estimate was calculated according to Luria and Delbruck (13)
as modified by Lea and Coulson (18) as described in the
legend to Table 1. Estimates of mutation rate using the mean
method were calculated as described by Capizzi and Jameson
(19) (described in the legend to Table 1) and verified by direct
solution of their transcendental equation 2.
RESULTS
Determining the Nature of the PALA-Resistant Variants by
Using the Luria-Delbruck Fluctuation Analysis. A fluctuation
analysis was performed on each of the cell lines to determine
the nature ofthe generation ofPALA-resistant variants-i.e.,
to distinguish between a spontaneous mutation event and an
adaptive event. Exponentially growing cells were plated as
described in Fig. 1 for both sets 1 and 2. In set 1, 2 x 105 cells
of each cell line were plated in 100-mm dishes; after 6 hr the
medium was replaced by selective medium containing a
PALA concentration equivalent to 9x LD50 for each respec-
tive cell line. Previous studies have shown that the colonies
arising under these conditions have amplified the CAD gene
(12). The data presented in Table 1 show that the variation in
these samples is consistent with Poisson variability, indicat-
ing that any large fluctuations that may be seen in set 2 must
be due to processes other than sampling error.
At the same time, exponentially growing cells were plated
as described for set 2. Two hundred cells of each cell line
were plated in replicate cultures and expanded to 2 X 105 cells
per plate. After attaining this density, the cells were
trypsinized, dispersed, and placed in a 100-mm dish. After 6
hr the medium was replaced with selective medium contain-
ing PALA at a final concentration of 9x LD50 for each cell
line, respectively. Results are presented in Table 1. In each
of the three cell lines studied, the variance significantly
exceeded the mean (P values < 10-), indicating that ampli-
fication of the CAD genes in these cell lines arose sponta-
neously.
Determination of Spontaneous Amplification Rates Through
Luria-Deibruck Fluctuation Analysis. Fluctuation analysis
also can be used to estimate the mutation rate of a given event
in mammalian cells. Mutation rates were determined for
WB20, GN5, and GP9. The tumorigenic cells demonstrate a
much greater rate of spontaneous CAD gene amplification
than the nontumorigenic WB20 cells (Table 1). By averaging
the rate values from Table 1 and additional determinations
(data not shown) and using both types of determinations
when possible (PO and method of means), the nontumorigenic
WB20 cells were found to amplify the CAD gene at a rate of
1.07 x 10-6 events per cell per generation. The moderately
tumorigenic GN5 cells and highly tumorigenic GP9 cells
yielded rates of 1.34 x 10-5 and 7.6 x 10-5 events per cell per
generation, respectively, 12 and 71 times higher than that of
the WB20 cells.
Repeated Measurement of Mutation Rate During Exponen-
tial Growth. The mutation rate measured above is contingent
on several assumptions, one being that the probability of the
event is constant throughout exponential growth. To address
this point, we determined the mutation rate for GP9 cells at
three different points during exponential growth. The muta-
tion rate remained reasonably constant through early, mid,
and late phases of exponential growth, with average values of
6.2, 5.3, and 13.8 x 10-5 mutants per cell per generation,
respectively.
Derivation and Characterization of Nontumorigenic and
Tumorigenic PALA-Resistant Subclones. The number of
PALA-resistant colonies that arise in a population will de-
pend on the rate of mutation (in this case the rate of CAD gene
amplification), the time of appearance of the variant cell, and
the reproductive capacity of the variant and nonvariant cells.
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Table 1. Fluctuation analysis of PALA-resistant (PALAR) variants in rat liver cell lines with
differing degrees of tumorigenicity
WB20 GN5 GP9
Set 1 Set 2 Set 1 Set 2 Set 1 Set 2
Replicate cultures, no. 79 56 39 51 40 23
No. of plates containing
the following no. of
PALAR colonies:
0 73 38 - 1
1 6 4 3 -
2 8 6
3 3 8 1
4 1 6 1
5-8t 3 10 16 4
9-16 28 9 4
17-32 - 2
33-64 1 18 8
65-129 - 1 22 3
Mean colonies per 0.076 0.82 10.18 7.98 65.75 34.96
replicate (r)
Variance 0.071 2.26 7.36 243.14 66.09 1050.95
Variance/mean 0.94 2.75 0.72 30.45 1.01 30.06
P valuer 0.64 <10-4 0.90 <10-4 0.46 <10-4
Mutation rate
PO calculation- 1.72 x 10-6 - 1.62 x 10-5 NA
Mean methodl 1.88 x 10-6 1.06 x 10-5 6.27 x 10-5
Data for plates in set 1 were obtained from aliquots of cells from the indicated parent populations,
which were placed in PALA concentrations equivalent to 9x the LD50 for each cell line (WB20 in 112.5
,uM, GN5 in 72 ,M, and GP9 in 81 /iM PALA). Data for plates in set 2 were obtained from aliquots of
200 cells from the original parent populations, propagated until a cell density of 2 x 105 cells was
obtained, and then plated for selection in the PALA concentrations indicated above.
tThe colonies per plate for each cell line within these intervals are as follows: WB20 cells set 2, 5(2) and
7. GN5 cells set 1, 6(3), 7(3), 8(4), 9(3), 10(7), 11(6), 12(4), 13(4), 14(2), 15, and 16; GN5 cells set 2, 5(4), 6(6),
7(3), 8(3), 9(3), 10(3), 11, 15, 16, 33, and 111; GP9 cells set 1, 51, 52, 53, 54, 57, 58, 59(2), 60(4), 61(3), 62(3),
66(3), 68(4), 69(2), 70(4), 71, 72, 74, 75(2), 76, 77, 83, and 87; GP9 cells set 2, 3, 4, 6, 7(2), 8, 12(2), 13, 15,
21, 24, 37, 38(2), 43, 48, 52, 60, 61, 68, 98, and 129. The subscript in parentheses indicates the number
of plates containing the indicated number of colonies when the number exceeds 1. For example, for
the WB20 cell line in set 2, two plates contained 5 colonies and one plate contained 7.
tObtained from the dispersion test for Poisson sampling (20).
§Calculated according to Luria and Delbruck (13) as modified by Lea and Coulson (18) from the
calculation ; = [(ln 2) (-ln Po)]/(Nt - No*) where PO represents the fraction of cultures with no
variants, ,t is the rate of amplification per cell per generation, and Nt and No* are, respectively, the
Nt (final cell number) and N. (initial cell number) adjusted for plating efficiency.
$Calculated according to Capizzi and Jameson (19) by the equation Cr = (CANt*) ln (CQNt), where C
is the number of replicate cultures, r is the average number ofvariants per culture, ,u is the amplification
rate per cell per generation, and Nt is Nt adjusted for plating efficiency. Given r, Nt, C, Cr is obtained,
and the corresponding value for CtNt is extrapolated from table 3 of ref. 19.
In designing the fluctuation analysis, Delbruck made several
assumptions that must be addressed here if the results are to
have any validity (see Discussion). To address these assump-
tions, we have isolated PALA-resistant subclones that have
undergone CAD gene amplification and characterized them
for their reproductive capacity in the absence of selection
pressure. In a previous study (12), cells were placed in PALA
concentrations equivalent to 9x LD50. Resistant colonies
emerged and were picked, expanded, analyzed for CAD gene
copy number, and found to be amplified (2- to 4-fold; ref. 12).
For the present study, several of these subclones were
characterized for their growth characteristics out of selective
medium to closely approximate the conditions that exist as
the cells are expanding during the fluctuation analysis. Re-
productive capacity of these subclones was measured by
using their cell cycling time and plating efficiency in the
absence of selection. While the plating efficiencies of the
PALA-resistant subclones are similar to that of the PALA-
sensitive cells, the cell cycle times may vary from slower to
comparable rates (data not shown).
We also propagated four WB20 PALA-resistant subclones
and four GP9 PALA-resistant subclones out of selection
media for various amounts of time to determine the stability
of the initial amplification. The cells were grown for 1-5
months out of selection (out of PALA-containing medium)
and then rechallenged at monthly intervals with the original
concentration of the drug (9x their LD50 values, respective-
ly). All PALA-resistant subclones demonstrated a plating
efficiency equivalent to that of the parental population when
rechallenged with the drug within 4 weeks after their emer-
gence. This indicates, that in the rat liver epithelial cells, the
CAD gene is amplified and retained in a stable state during the
initial weeks of growth, and loss of resistant colonies is
negligible during the initial expansion of the culture before
selection (unpublished data).
DISCUSSION
In this study, we have used the Luria-Delbruck fluctuation
analysis to show that: (i) amplification of the CAD gene in the
rat liver epithelial cells is arising in a spontaneous fashion in
the population, and (ii) the rate of spontaneous CAD gene
amplification is significantly higher in the tumorigenic cell
lines compared with the nontumorigenic cell line.
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Biological Considerations Relevant to the Estimation of
Mutation Rate by Using the Luria-Delbrtick Fluctuation Anal-
ysis. The variation in colony number seen in Table 1 unequiv-
ocally demonstrates the spontaneous nature of the amplifi-
cation of the CAD gene in these cells. Our data indicate that
PALA is not facilitating the emergence of a small subpop-
ulation of cells that is PALA resistant; rather we find that
amplification of the CAD locus occurs spontaneously in all
rat liver epithelial cell lines studied. These results are con-
sistent with those reported for CAD gene amplification in
another rodent, the hamster cell lines studied by Stark and
co-workers (21).
Although the fluctuation analysis is adequate for determin-
ing the spontaneity or nonspontaneity of a given event as
discussed above, the use of this procedure for accurate
determination of rate requires attention to a multitude of
experimental conditions (22). In the fluctuation-type exper-
iment outlined in Fig. 1, the number of PALA-resistant
colonies in a population will depend not only on the rate at
which they arise but also on their time of appearance (early
or late in the expansion of the culture) and the reproductive/
survival capacity of the individual colonies. Assumptions
concerning these variables for the variant (PALA-resistant
cells) and wild-type cells determine whether the fluctuation
analysis can be applied to the estimation of gene amplifica-
tion. The accuracy and validity of the rate analysis rest on
how well these assumptions are met. We have addressed
these assumptions in an experimental fashion where possible
and discuss them in this section.
The fluctuation analysis, as originally devised, was used to
determine the probability of a discrete event, the generation
of a phage-resistant bacterium. When the bacterium was
resistant, it lived; when it wasn't, it died (13). Drug resistance
can be assessed by gene amplification in a similar manner if
the conditions for survival are strictly defined. Under our
conditions, we require that the surviving colony be resistant
to 9x LD50 of the drug. At this stringency of selection, we
have shown that the cells are truly resistant (they may be
propagated in that concentration of the drug without loss of
plating efficiency), and when analyzed, the basis of the
resistance is amplification of the CAD gene (12). Amplifica-
tion of this gene is the only reported mechanism of resistance
to PALA and in our studies is the only observed mechanism
of resistance in rat liver epithelial cells.
The fluctuation analysis requires that the probability of
mutation for an individual cell be directly related to its growth
rate (13). Our experiments are done under logarithmic-phase
growth conditions, where the growth rate is constant and
reproducible. We have estimated the mutation (amplifica-
tion) rate during early, mid, and late logarithmic growth and
find that the rate is also constant. This allows us to conclude
that the probability of variation in our system is constant with
exponential growth and that this assumption of the fluctua-
tion analysis has been met.
Comparative plating efficiency of the cells is an important
variable in two aspects of this analysis. At the initiation of our
experiments to apply the fluctuation analysis to this biolog-
ical process, the cultures of the different cell lines are
trypsinized and dispersed into individual culture dishes (100-
mm dishes). The different cell lines may vary in their plating
efficiency. For our experiments the plating efficiency of each
cell population has been determined and is taken into account
in the subsequent calculations for the analysis. Second,
during the course of our expansion of the cultures and their
subsequent placement into selection conditions, the cells
must be trypsinized and replated. If the variant (amplified)
cells had a lower (or higher) plating efficiency than nonvari-
ant cells, an artifactual depletion (or elevation) of their
number would result and be scored as an aberrant rate. To
test for this possibility, we determined the plating efficiency
of variant and nonvariant cells under nonselective (expan-
sion) conditions for both the WB20 and the GP9 cell lines. The
two populations for each cell line studied (WB20 and GP9;
variant and wild type) had similar plating efficiencies under
these conditions; hence, a differential plating efficiency can-
not account for the rate difference we observe for the
spontaneous amplification event.
If the generation and detection of PALA-resistant colonies
is to represent the rate of gene amplification, both the growth
of variant (amplified) and wild-type (nonamplified) cells must
be exponential and have equal rates. Unequal growth rates of
these two populations would skew the final number of
colonies that were tabulated and misrepresent the rate de-
termination (23). To address this question we propagated
variant and nonvariant cells separately under conditions that
were used for the expansion of the culture (i.e., complete
medium not containing any drug). Their growth rates were
similar. The plating efficiencies of the PALA-resistant sub-
clones plated in nonselective media are comparable to that of
the PALA-sensitive (wild-type) cells. The cell cycling time
varies for the different subclones. In both cases, that of the
WB20 cells and the GP9 cells, the subclones exhibited, on
average, - 15% greater cell cycle time than the corresponding
parental populations. The values range from similar cycle
times to slightly longer cycling times. This indicates that the
PALA-resistant colonies have no growth advantage as the
culture is being propagated under nonselective conditions.
The slightly slower cycling times observed with some of the
subclones would eventually alter the composition of the
population but the minimal differences observed would not
be a major consideration during the short propagation time
during the fluctuation analysis (-4-6 days). These results
suggest that the estimation of the rate of gene amplification
in these cells is a minimal value and that the number of
PALA-resistant colonies detected when the cells are placed
under conditions of selection cannot be attributed to a
differential growth rate of one subpopulation vis a vis the
other during the expansion of the culture.
N further requirement for the analysis is that, during
selection, the cells be plated under conditions to allow for the
growth of independent colonies; no cross-feeding may occur.
Selection of PALA-resistant colonies may be circumvented
by the transfer of nutrients from one cell to another to
overcome the aspartate transcarbamylase inhibition. In our
experiments the cells are plated at a maximum of 2 x 105 per
100-mm dish, a density that allows for the growth of well-
separated, individual colonies. In support of this claim, we
have tested the resistance of numerous of these colonies and
have found them to breed true when rechallenged with the
drug (12).
The fluctuation analysis requires that in order for the rate
to be accurately assessed, no preexisting variant cells can be
seeded at the initiation of the expansion of the cultures. The
variants that are scored must arise during the expansion of
the parallel cultures. Our cultures begin with -100 viable
cells. If a preexisting variant were present in the initial 100
cells, and if it had a doubling time equivalent to that of the
wild-type cell population (as shown previously), its contri-
bution to the number of colonies scored as the cells are placed
in selection would be great; >1000 colonies per 105 cells
would be visualized. Since this was not found in any of our
analyses, we conclude that the number of preexisting variants
in the population is small or nonexistent and that our rate
determination is not affected. We are indeed measuring the
spontaneous appearance of drug-resistant/CAD-gene-ampli-
fied cells.
Finally, for this analysis it is assumed that the rate of back
mutation (deamplification) is negligible. The effect of reverse
mutation on the estimated rate of amplification depends on
the absolute number of cells available for the event. Given the
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relatively rare number of amplification events, the reverse
rate would have to be extraordinarily high to have any effect.
We have analyzed the stability of our PALA-resistant colo-
nies, both at the earliest time possible and after expansion,
and find that in the WB20 and GP9 rat cell lines the PALA
resistance is stable at early times after emergence. We have
grown the cells in the absence of selection for 1-5 months and
find that during the first month of propagation, they have a
similar plating efficiency to the drug-resistant parental pop-
ulation when rechallenged with the selecting concentration of
the drug. This determination gives us an indication of the
stability of the amplification unit after it has emerged as a
colony.
Data from the fluctuation analysis and subsequent controls
have allowed us to estimate the rate of spontaneous gene
amplification. Mutation rates were estimated via a fluctuation
analysis using the PO method and the method of means (13,
19). The P0 method was modified according to the work of
Lea and Coulson (18), Newcombe (24), and Armitage (25). Li
et al. (26, 27) have reported that there is an optimal value for
PO (between the range of 0.15 and 0.8), which will maximize
the sensitivity of the fluctuation analysis. They have devel-
oped guidelines for the optimization of the values Po, Nt, and
C to improve the reliability of the estimation of ,u. We have
followed these guidelines in generating data for the estimation
of ,t in these studies. The method of means measures the rate
from an alternative perspective-namely, equating the ob-
served average rate of variants to its expectation. In our
hands, with these cells, both methods are in agreement.
In this study we show quantitatively that individual rat
liver epithelial cell lines, which differ in their ability to form
tumors, have an inherently different rate of amplifying the
CAD gene. The nontumorigenic WB20 cell line amplifies at a
frequency that is somewhat high for a mutational event in
mammalian cells, an average of 1.07 x 10-6 events per cell
per generation. The GN5 cell line, which will form tumors in
some but not all animals into which it is injected, spontane-
ously amplifies the CAD gene at a rate that is more than an
order of magnitude higher than that measured for the WB20
cells (on average, 1.34 x 10-5 events per cell per generation).
The highly tumorigenic GP9 cell line demonstrates a rate of
CAD gene amplification (on average, 7.6 x 10-5 events per
cell per generation) that is >70 times higher than that
measured in the WB20 cell line. It is this inherent ability to
amplify the CAD gene and the difference between these cell
lines that we would like to understand on a molecular level.
Biological Significance. The rate of gene amplification re-
ported for the tumorigenic cell lines in this study (1-7 x 10-5
events per cell per generation) is quite high compared to the
rate of point mutations usually observed in mammalian cells
(10-7-10-1 events per cell per generation) (14, 28, 29). A
frequency of CAD gene amplification has been reported for
a Syrian hamster line (-2 x 10-5) (21). If our estimated rate
is indicative of amplification rates in tumorigenic cells in
general, it is expected that the types of phenotypic changes
that result from gene amplification would make a significantly
greater contribution to the mutagenic burden of tumorigenic
cells than that produced by point mutations. Recent studies
on the frequency of large spontaneous deletions suggest that
these types of rearrangements are also occurring quite often
(30). The observation of deletions and amplifications in
tumorigenic cells is well documented and may provide the
mechanisms underlying the phenotypic and genotypic heter-
ogeneity seen in neoplastic cells.
Several studies have linked the frequency and extent of
amplification of specific oncogenes with the malignancy of
the disease (31-33). In neuroblastomas, the frequency and
extent of N-myc amplification is reported to be a better
prognostic indicator than any other determinant for that
disease (31). While in some cases amplification of specific
oncogenes is correlated with disease progression, amplifica-
tion of other oncogenes, often in the same cells, is not (33).
Our results provide a framework for understanding these
clinical data. The more tumorigenic a cell, the higher the
probability that it will amplify a segment of its genome. This
is consistent with the multiple reports of amplification in
neoplastic tissue. We also know that the amplified copies are
eventually lost unless selection pressure is exerted upon that
population (9, 10). The oncogene products that correlate with
disease progression must be conferring a growth advantage
on that cell population in that tumor. Studies on gene
amplification in these tumors could provide us with a tool to
identify signals important in the progression of neoplasia.
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